LOGIN  |  REGISTER
Assertio
Terns Pharmaceuticals

UnitedHealth Provides Updates on Annual Shareholder Meeting, Board Actions

June 05, 2024 | Last Trade: US$454.00 131.04 -22.40

- / Jun 05, 2024 / Business Wire / UnitedHealth Group (NYSE: UNH) provided updates on its 2024 annual shareholder meeting and actions by its Board of Directors.

Shareholders elected all those nominated to the Board: Charles Baker, Timothy Flynn, Paul Garcia, Kristen Gil, Stephen Hemsley, Michele Hooper, F. William McNabb III, Valerie Montgomery Rice, M.D., John Noseworthy, M.D., and Andrew Witty.

UnitedHealth Group directors stand for election annually.

Shareholders also:

  • Approved the advisory resolution on the Company’s executive compensation.
  • Ratified Deloitte & Touche LLP as the Company’s independent registered public accounting firm.
  • Voted against the shareholder proposal seeking a political contributions congruency report.

At its regular quarterly meeting, the Board authorized payment of a cash dividend of $2.10 per share, to be paid June 25, 2024, to common stock shareholders of record as of the close of business June 17, 2024.

About UnitedHealth Group

UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com and follow UnitedHealth Group on LinkedIn.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page